AI news
AI model reviews
AI tools
How-to guides
Our staffAboutContact

Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

Isomorphic Labs has closed a $5B Series C co-led by Greenoaks and Sequoia, six months after a $2.1B Series B. Here's who's paying, who gains and what's still unproven.

scientist using pipette with test tubes in lab
Photo: Julia Koblitz on Unsplash

Isomorphic Labs has raised $5 billion in a Series C funding round as it seeks to take its drug candidates to clinical trials. It's the AI drug company's second multibillion-dollar raise in six months, marking the second time in six months it has done one, after a $2.1 billion Series B in May.

Who's paying

Greenoaks and Sequoia Capital co-led the series C. New investor Andreessen Horowitz joined, and every existing backer came back too: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. Alphabet's investment is described as continued and significant in the company's announcement, which also calls the round oversubscribed.

The May Series B was led by Thrive Capital. Add the two rounds together and that's $7.1 billion raised in about six months.

Isomorphic didn't disclose a valuation. Bloomberg reported earlier this month that the company was looking to raise at a $50 billion valuation, but that figure isn't confirmed by the company.

Who gains

Isomorphic gets the obvious prize: runway. The company says the money will go into its drug design engine, called IsoDDE, expanding into new biology and building AI-first translational and clinical development infrastructure. That last item matters most. Running trials is a different business from designing molecules.

Pharma partners benefit indirectly. The lab has struck deals with Eli Lilly, Novartis and Johnson & Johnson, and the 2024 alliances with Lilly and Novartis were valued at about $3 billion combined, including milestones. A better-funded partner is more likely to deliver on those programs, though milestone payments only arrive if the science works.

Investors gain only if molecules succeed in people. Their payoff is a bet on the pipeline, not on anything that's reached patients yet.

The stakes for the AI market

Isomorphic is the best-known test of whether AI can do more than speed up the early stages of drug discovery. It builds on DeepMind's AlphaFold, and Demis Hassabis and John Jumper won the Nobel Prize in chemistry for that work. Hassabis, Isomorphic's founder and CEO, left his position as head of DeepMind to focus on drug discovery and moved into a chairman role there.

The company says its work is yielding "positive preclinical results" in oncology and immunology. Preclinical is the key word. The announcement doesn't give a date for a first clinical trial, and I couldn't find one in any of the coverage I read.

Honestly, I think the size of these two rounds says more about investor appetite for AI than about drug-development evidence. Money at this scale buys time and talent. It doesn't buy a trial result.

What happens next

The next milestone is clinical entry. Hassabis says the round lets the company focus on "driving our first therapeutic programs towards clinical trials". Until a candidate is dosed in humans, the $5 billion is a statement of confidence, and a large one.

The company is creating a partner ecosystem to study the mechanisms behind disease, and it's headquartered in London with offices in Cambridge, Massachusetts and Lausanne, Switzerland. I'd expect more partner announcements before any trial news, since those are quicker to arrange, but that's a guess. If you follow AI in biotech, the thing to watch is the first trial registration, not the next funding round. You can read the company's own announcement on the Isomorphic Labs site.

Keep reading